News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GlaxoSmithKline (GSK) Diabetes Drug Faces U.S. Approval Delay


8/2/2013 11:23:49 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

U.S. regulators have pushed back an approval decision on GlaxoSmithKline's experimental diabetes drug albiglutide by three months until April 15, 2014, Britain's biggest drugmaker said on Friday. A separate filing for the drug in Europe is progressing on schedule. The once-weekly treatment for type 2 diabetes belongs to the same class of injectable GLP-1 drugs as Victoza, from Novo Nordisk, and Byetta and Bydureon, from Bristol-Myers Squibb and AstraZeneca.

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters
Read at Nasdaq
Read at News Release

comments powered by Disqus
   
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES